Histotripsy for Renal Cell Carcinoma (HRCC)
Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Study Design and Methodology
This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.
Procedure
Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.
Assessment
Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.
Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.
Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.
Admission and follow-up
Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.
After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.
Potential risk and discomfort
Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.
Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.
Short-term effects
- Mild pain or soreness that usually responds to oral pain medication
- Low-grade fever and flu-like symptoms that typically resolve within 48 hours
- Temporary skin redness at the treatment site
- Mild abdominal discomfort
- Temporary changes in renal function tests
- Possible nausea or fatigue
- Transient haematuria
Potential serious complications
- Temporary decrease in kidney function
- Potential damage to surrounding organs (liver, lung, bowel, or stomach)
- Severe pain
- Need for extended hospital stay or additional treatment for serious complications
- Skin ulcer / necrosis requiring interventions
- Vascular thrombosis / dissection
Long-term complications
• Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.
In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.
Statistical analysis
Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.
DATA AND BIOLOGICAL SAMPLES HANDLING
Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.
Consent
Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.
Conflicts of interests
All investigators and funding bodies have no financial interests in the study.
Research ethics
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Professor Matthew Kin-liang CHIU, PhD
- Telefonní číslo: +852 22554352
- E-mail: mklc2@hku.hk
Studijní místa
-
-
-
Hong Kong, Hongkong
- Nábor
- Gleneagles Hospital Hong Kong
-
Kontakt:
- Professor Matthew Kin-liang CHIU, PhD
- Telefonní číslo: +852 22554352
- E-mail: mklc2@hku.hk
-
Dílčí vyšetřovatel:
- Wing Hang Vince Lau, MBBS, FHKCR, FHKAM
-
Dílčí vyšetřovatel:
- Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM
-
Dílčí vyšetřovatel:
- Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR
-
Dílčí vyšetřovatel:
- Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK
-
Dílčí vyšetřovatel:
- Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM
-
Dílčí vyšetřovatel:
- Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
-
Dílčí vyšetřovatel:
- Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM
-
Dílčí vyšetřovatel:
- Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥ 18 years old
- Fit for general anaesthesia
- Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
- With or without distant metastases
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date).
Exclusion Criteria:
- Refusal to take part in clinical trial
- Not fit for general anaesthesia
- Poor general condition with limited life expectancy
- Uncontrolled coagulopathy
- The treatment of the tumour will not allow for an adequate margin as determined by the investigator
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System
|
Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To assess efficacy
Časové okno: 90 days post procedure
|
Successful treatment percentage at 90 days on MRI/CT post-procedure |
90 days post procedure
|
|
To assess treatment safety
Časové okno: At 30 days
|
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher |
At 30 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Pain score assessment before and after histotripsy
Časové okno: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Novotvary podle histologického typu
- Novotvary, žlázové a epiteliální
- Adenokarcinom
- Urologické novotvary
- Karcinom
- Novotvary ledvin
- Karcinom, renální buňka
Další identifikační čísla studie
Další identifikační čísla studie
- GHK-2026-005
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .